OSTEOPORE LIMITED — Capital/Financing Update 2020

Jul 1, 2020

==> picture [130 x 44] intentionally omitted <==

ASX RELEASE│OSTEOPORE LIMITED

OSTEOPORE SIGNS INITIAL U.S. DISTRIBUTION AGREEMENT

2 JULY 2020: Osteopore Limited (ASX: OSX) (“Osteopore” or the “Company”) , a revenue generating medical technology company that has commercialised a range of patented 3D printed bioresorbable products, is pleased to announce it has signed an agreement with US based Bioplate Inc to market, promote and sell Osteopore products into the US market.

Bioplate is an established market leader in providing cranial fixation solutions for neurosurgery around the world. With two decades of experience in product innovation and sales, they have strong relationships with doctors, health professionals, hospitals and health services, as well as significant sales and client support necessary for market penetration of the technology.

Under the terms of the two year agreement, Bioplate will distribute Osteopore products on a nonexclusive basis for cranial and neurosurgery procedures. The distribution agreement covers select states within the US market, covering California, Arizona, Texas, Ohio, Wyoming Indiana and Puerto Rico. Bioplate will cover all technical support requirements for the Osteopore products as well as educational and training support.

Osteopore plans to work closely with Bioplate to initially penetrate key US clinical institutions and support them with hospital listings, driving product adoption and generating sales. The training program for Bioplate sales representatives will begin shortly and Osteopore will be involved in the initial promotion to a number of influential neurosurgeons over the coming weeks.

While Osteopore continues to grow its underlying revenue base from its existing, primarily Asian distribution network, this is the Company’s first US distribution agreement since its IPO in 2019, and the company will continue to explore additional distributors for other regions to facilitate market penetration and sales, as well as maximise the improved patient outcomes available through its unique technology.

Bioplate has already received small orders from the University of California and Stanford in the San Francisco area and will provide Osteopore with quarterly forecasts for demand throughout the agreement period.

Osteopore chief executive officer Khoon Seng Goh said “The current bone graft substitute market is worth around US$4 billion, and sales of permanent implants are estimated at over US$100 billion annually. With a large portion of this opportunity sitting within the US, penetrating this region is a major strategic objective for the business. We continue to focus on development and manufacturing of our products and building additional commercial partnerships with parties who will be responsible for the sales and distribution of the products into other US territories”

This announcement has been approved for release by the Board of Osteopore.

For more information please contact: Geoff Pocock Executive Director Osteopore Limited +61 4 1219 4373 geoff_pocock@osteopore.com

Osteopore Limited (ACN 630 538 957)│ASX:OSX│16 Ord Street, West Perth│+618 9482 0500│www.osteopore.com

==> picture [130 x 44] intentionally omitted <==

About Osteopore Limited

Osteopore Ltd is an Australian and Singapore based medical technology company commercialising a range of bespoke products specifically engineered to facilitate bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent protected scaffolds are made from proprietary polymer formulations, that naturally dissolve overtime to leave only natural. healthy bone tissue, significantly reducing postsurgery complications that are commonly associated with permanent bone implants.

About Bioplate Inc

Bioplate designs and manufactures cranial closure and bone fixation systems for neurosurgery. The company was founded in 1995 and continues to share the founders’ commitment to patient safety and practitioners’ insight into the needs of the operating room. A focus on safety and effectiveness remains at the core of the company’s philosophy. With two decades of experience in product innovation and sales, they have built a reputation around high quality precision products and superior service. Bioplate is a privately held corporation based in Los Angeles, CA.

Forward Looking Statements

Statements contained in this release, particularly those regarding possible or assumed future performance, revenue, costs, dividends, production levels or rates, prices or potential growth of Osteopore Limited, are, or may be, forward looking statements. Such statements relate to future events and expectations and, as such, involve known and unknown risks and uncertainties. Actual results may differ materially from those expressed or implied by these forward-looking statements depending on a variety of factors.

Osteopore Limited (ACN 630 538 957)│ASX:OSX│16 Ord Street, West Perth│+618 9482 0500│www.osteopore.com